↓ Skip to main content

CCR3 Is Associated with the Death of a Photoreceptor Cell-line Induced by Light Exposure

Overview of attention for article published in Frontiers in Pharmacology, April 2017
Altmetric Badge

Mentioned by

twitter
1 X user

Readers on

mendeley
23 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
CCR3 Is Associated with the Death of a Photoreceptor Cell-line Induced by Light Exposure
Published in
Frontiers in Pharmacology, April 2017
DOI 10.3389/fphar.2017.00207
Pubmed ID
Authors

Yoshiki Kuse, Kazuhiro Tsuruma, Yusuke Kanno, Masamitsu Shimazawa, Hideaki Hara

Abstract

The C-C chemokine receptor type 3 (CCR3) is the receptor for eotaxins (CCL-11, 24, 26), RANTES (CCL-5) and MCP-3 (CCL-7). It was reported that an inhibition of CCR3 by antagonists or antibodies reduces the degree of laser-induced choroidal neovascularization in mice, a model for wet age-related macular degeneration (AMD). Although several chemokine receptors have the potential of reducing the degree of the chronic inflammation in experimental dry AMD, the association of CCR3 remains unknown. The purpose of this study was to determine the role played by CCR3 in the death of 661W cells which are cells of a murine photoreceptor-derived cell line as an in vitro model of dry AMD. The expression of CCR3 was increased in the 661W cells after light exposure. Inhibition of CCR3 reduced the rate of cell death induced by light exposure. A blockade of CCR3 signaling by CCR3 silencing and two kinds of CCR3 antagonists, SB 328437 and SB 297006, reduced the rate of light-induced cell death. In addition, CCR3 inhibition decreased the level of reactive oxygen species and the activation of caspase-3/7 induced by light exposure. These findings indicated that the CCR3 blockade should be considered for the treatment of the dry AMD.

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 23 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 23 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 7 30%
Student > Ph. D. Student 3 13%
Student > Bachelor 2 9%
Student > Master 2 9%
Student > Postgraduate 1 4%
Other 0 0%
Unknown 8 35%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 5 22%
Pharmacology, Toxicology and Pharmaceutical Science 4 17%
Medicine and Dentistry 3 13%
Agricultural and Biological Sciences 2 9%
Neuroscience 1 4%
Other 0 0%
Unknown 8 35%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 18 April 2017.
All research outputs
#20,414,746
of 22,965,074 outputs
Outputs from Frontiers in Pharmacology
#10,144
of 16,235 outputs
Outputs of similar age
#269,995
of 310,294 outputs
Outputs of similar age from Frontiers in Pharmacology
#142
of 221 outputs
Altmetric has tracked 22,965,074 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 16,235 research outputs from this source. They receive a mean Attention Score of 5.0. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 310,294 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 221 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.